Spherix incorporated (NASDAQ: SPEX) an innovator in the field of biotechnology for the treatment in diabetes, metabolic syndrome and atherosclerosis and provider of technical and legal advisory services on food, Supplement, biotechnology and pharmaceutical companies announced, given that achieves statistically significant reduction of the VLDL and LDL cholesterol, if genetically modified his drug candidates SPX-106, mice Dyslipidemia vulnerable in combination with Dtagatose (SPX-106T) for nine weeks. The Aortas these mice showed also cuts in the amount of atherosklerotische lesions lesion measured area in response to the treatment. This lipoprotein analysis and lesion results form the last data from the study, whose previous triglycerides result first on June 2, 2011 was announced.
Treatment of animals, with a series of low doses of SPX-106T twice daily significantly reduced VLDL by 35% (of 127 mg / dl to 82 mg / dl) and LDL by 18% (from 141 116 mg / DL) (p = 0.05). Importantly, reduced the same therapy also atherosclerotic lesions range in the aortic arch to less than half the value of the untreated group (chart available at http://www.spherix.com/pdf/press/PRgraphic9-12-11.pdf). The aortic arch is the region where ship first developed disease. The thoracic aortic include more studies and models fully developed into the high serum triglycerides, illness of spreads on the ship of the aortic arch. The study was not driven on an atherosclerosis endpoint and the Aortas was made for the post-hoc analysis, when it turned out the effectiveness of the SPX 106T reduction of triglycerides and cholesterol.
D-tagatose alone and combination judged this year initiated Spherix the preclinical development of SPX 106T as a treatment for hypertriglyceridemia in one arm of a trial. The first studies that specifically test for SPX-106T are nearing completion and results will be this fall. The company plans to launch an initial human efficacy to study in the first quarter of 2012. Rapid progression in the clinic is made possible by the experienced team at the company.
"Two global clinical trials for a diabetes indication, that only successfully concluded, has Spherix to design staff and running new Dyslipidemia suffer much faster than other companies of comparable size," notes Claire Kruger, Chief Executive Officer of Spherix Dr. "The preclinical pipeline of our Biospherics subsidiary can be expanded quickly in the clinical phase, because the company can perform successfully several studies at the same time."
Treatment of animals, with a series of low doses of SPX-106T twice daily significantly reduced VLDL by 35% (of 127 mg / dl to 82 mg / dl) and LDL by 18% (from 141 116 mg / DL) (p = 0.05). Importantly, reduced the same therapy also atherosclerotic lesions range in the aortic arch to less than half the value of the untreated group (chart available at http://www.spherix.com/pdf/press/PRgraphic9-12-11.pdf). The aortic arch is the region where ship first developed disease. The thoracic aortic include more studies and models fully developed into the high serum triglycerides, illness of spreads on the ship of the aortic arch. The study was not driven on an atherosclerosis endpoint and the Aortas was made for the post-hoc analysis, when it turned out the effectiveness of the SPX 106T reduction of triglycerides and cholesterol.
D-tagatose alone and combination judged this year initiated Spherix the preclinical development of SPX 106T as a treatment for hypertriglyceridemia in one arm of a trial. The first studies that specifically test for SPX-106T are nearing completion and results will be this fall. The company plans to launch an initial human efficacy to study in the first quarter of 2012. Rapid progression in the clinic is made possible by the experienced team at the company.
"Two global clinical trials for a diabetes indication, that only successfully concluded, has Spherix to design staff and running new Dyslipidemia suffer much faster than other companies of comparable size," notes Claire Kruger, Chief Executive Officer of Spherix Dr. "The preclinical pipeline of our Biospherics subsidiary can be expanded quickly in the clinical phase, because the company can perform successfully several studies at the same time."
